Details of the Drug

General Information of Drug (ID: DMERWUC)

• Drug Name: Organon
• Synonyms: Allylestrenol; Allyloestrenol; Allyloestrenolum; Gestanin; Gestanol; Gestanon; Gestanyn; Orageston; Perselin; Turinal; Allilestrenolo [DCIT]; Alilestrenol [INN-Spanish]; Allylestrenol [INN:JAN]; Allylestrenol(jan); Allylestrenolum [INN-Latin]; Gestanon-r; Perselin (TN); Allylestrenol (JAN/INN); (17beta)-17-prop-2-en-1-ylestr-4-en-17-ol; (8R,9S,10R,13S,14S,17R)-13-methyl-17-prop-2-enyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol; 17-(2-Propenyl)estr-4-en-17-ol; 17-Hydroxy-17-alpha-allyl-4-estrene; 17-alpha-Allyl-17-beta-hydroxy-4-estrene; 17-alpha-Allyl-17-beta-hydroxy-delta(sup 4)-estren; 17-alpha-Allyl-3-deoxy-19-nortestosterone; 17-alpha-Allyl-4-oestrene-17-beta-ol; 17-alpha-Allylestr-4-en-17-beta-ol; 17-alpha-Allylhydroxy-19-nor-4-androstene; 17.alpha.-Allyl-17-.beta.-hydroxy-.delta.(sup 4)-estren; 17.alpha.-Allyl-17.beta.-hydroxy-4-estrene; 17.alpha.-Allyl-3-deoxy-19-nortestosterone; 17.alpha.-Allyl-4-destrene-17.beta.-ol; 17.alpha.-Allyl-4-estren-17.beta.-ol; 17.alpha.-Allyl-4-oestrene-17.beta.-ol; 17.alpha.-Allylestr-4-en-17.beta.-ol; 17.alpha.-Allylestrenol; 17alpha-Allyl-17beta-hydroxy-4-estrene; 17alpha-Allyl-19-nor-delta-4-androstene-17beta-ol; 17alpha-Allyl-3-deoxy-19-nortestosterone; 17alpha-Allyl-4-destrene-17beta-ol; 17alpha-Allyl-4-estren-17beta-ol; 17alpha-Allyl-4-oestrene-17beta-ol; 17alpha-Allylestr-4-en-17beta-ol; 17alpha-Allylestrenol; 21-Methylene-19-nor-17-alpha-preg-4-en-17-ol; 3-Deoxy-17-alpha-allyl-19-nortestosterone

Indication

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Preclinical	[1]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 1:
  Molecular Weight (mw); 300.5
  Logarithm of the Partition Coefficient (xlogp); 5.3
  Rotatable Bond Count (rotbonds); 2
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 1
• Chemical Identifiers:
  Formula: C21H32O
  IUPAC Name: (8R,9S,10R,13S,14S,17R)-13-methyl-17-prop-2-enyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol
  Canonical SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(CC=C)O)CCC4=CCCC[C@H]34
  InChI: InChI=1S/C21H32O/c1-3-12-21(22)14-11-19-18-9-8-15-6-4-5-7-16(15)17(18)10-13-20(19,21)2/h3,6,16-19,22H,1,4-5,7-14H2,2H3/t16-,17+,18+,19-,20-,21-/m0/s1
  InChIKey: ATXHVCQZZJYMCF-XUDSTZEESA-N
• Cross-matching ID:
  PubChem CID: 235905
  ChEBI ID: CHEBI:31189
  CAS Number: 432-60-0
  DrugBank ID: DB01431
  TTD ID: D07PNC
  INTEDE ID: DR0068

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glycine transporter GlyT-1 (SLC6A9)	TTHJTF7	SC6A9_HUMAN	Blocker	[2]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Androgen receptor (AR)	OTUBKAZZ	ANDR_HUMAN	Gene/Protein Processing	[4]

Molecular Expression Atlas of This Drug

• ICD Disease Classification: 06 Mental, behavioural or neurodevelopmental disorder
• Disease Class: ICD-11: 6A20 Schizophrenia
• The Studied Tissue: Pre-frontal cortex
• The Studied Disease: Schizophrenia [ICD-11:6A20]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Glycine transporter GlyT-1 (SLC6A9)	DTT	SLC6A9	4.94E-01	-0.09	-0.34
Glycine transporter GlyT-1 (SLC6A9)	DTT	SLC6A9	1.64E-01	-0.03	-0.17
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	4.66E-01	4.25E-02	1.20E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	4.75E-01	5.15E-02	3.64E-01

References

• [1] Receptor binding of allylestrenol, a progestagen of the 19-nortestosterone series without androgenic properties. J Steroid Biochem. 1985 Aug;23(2):165-8.
• [2] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [3] Identification of the human P450 enzymes involved in the in vitro metabolism of the synthetic steroidal hormones Org 4060 and Org 30659. Xenobiotica. 2002 Feb;32(2):109-18.
• [4] Effect of anti-estrogens on the androgen receptor activity and cell proliferation in prostate cancer cells. Urol Res. 2004 Dec;32(6):406-10. doi: 10.1007/s00240-004-0424-8. Epub 2004 Aug 14.